Skip to content
10-Q

Quarterly Report

TETRAPHASE PHARMACEUTICALS INC

0001564590-20-022821

← back to feed
Filed
May 7, 2020 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · May 6, 2020 7.26M sh
Operating Cash Flow Q1 2020 · Mar 31, 2020 −$11.16M
Operating Cash Flow Q1 2020 · Mar 31, 2019 −$20.12M
Cash And Equivalents Q1 2020 · Mar 31, 2020 $26.15M
Cash And Equivalents Q1 2020 · Dec 31, 2019 $21.24M
Stockholders Equity Q1 2020 · Mar 31, 2020 $27.46M
Stockholders Equity Q1 2020 · Dec 31, 2019 $23.17M
Stockholders Equity restated Q1 2020 · Mar 31, 2019 $62.92M
Stockholders Equity Q1 2020 · Dec 31, 2018 $79.68M
Current Liabilities Q1 2020 · Mar 31, 2020 $8.14M
Current Liabilities Q1 2020 · Dec 31, 2019 $9.77M
Current Assets Q1 2020 · Mar 31, 2020 $29.82M
Current Assets Q1 2020 · Dec 31, 2019 $26.49M
Total Assets Q1 2020 · Mar 31, 2020 $37.35M
Total Assets Q1 2020 · Dec 31, 2019 $36.39M
Sga Expense Q1 2020 · Mar 31, 2020 $10.67M
Sga Expense Q1 2020 · Mar 31, 2019 $13.31M
Rd Expense Q1 2020 · Mar 31, 2020 $1.89M
Rd Expense Q1 2020 · Mar 31, 2019 $6.74M
Net Income Q1 2020 · Mar 31, 2020 −$12.12M
Net Income Q1 2020 · Mar 31, 2019 −$19.49M
Operating Income Q1 2020 · Mar 31, 2020 −$12.26M
Operating Income Q1 2020 · Mar 31, 2019 −$19.04M
Revenue Q1 2020 · Mar 31, 2020 $1.76M
Revenue Q1 2020 · Mar 31, 2019 $1.27M
Capex Q1 2020 · Mar 31, 2019 $98K